Compare OCG & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCG | ARTL |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.5M |
| IPO Year | 2019 | N/A |
| Metric | OCG | ARTL |
|---|---|---|
| Price | $0.67 | $1.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 450.5K | 27.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.85 |
| 52 Week High | $19.29 | $28.60 |
| Indicator | OCG | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 42.77 |
| Support Level | $0.04 | $1.10 |
| Resistance Level | $4.24 | $1.50 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 11.14 | 33.33 |
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.